Further, the mutational status of CXCR4 in lymphoplasmacytic lymphoma (LPL) has been shown to influence disease burden and response to targeted therapies, further underscoring the prognostic role of genomic alterations [11,12]. Here, CXCR4 is linked to lymphoplasmacytic lymphoma.